Factored stochastic tree modeling for medical decision making Gordon Hazen Northwestern University Rowland Chang Northwestern University James Pellissier.

Slides:



Advertisements
Similar presentations
Measuring burden of disease Introduction to DALYs FETP India.
Advertisements

PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
Markov Models: Overview Gerald F. Kominski, Ph.D. Professor, Department of Health Services.
Markov versus Medical Markov Modeling – Contrasts and Refinements Gordon Hazen February 2012.
1 Parametric Sensitivity Analysis For Cancer Survival Models Using Large- Sample Normal Approximations To The Bayesian Posterior Distribution Gordon B.
Stroke. Stroke Facts About 795,000 Americans experience a Stroke (or Brain Attack) each year. About 610,000 of these are first attacks and 185,000 are.
Nov M. Huang Northwestern Univ. 1 Markov Chain Population Models in Medical Decision Making Gordon Hazen Min Huang Northwestern University.
Introduction to decision modelling Andrew Sutton.
Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
EXPECTED OUTCOMES The study will provide information on the impact of tobacco use on health from epidemiological, social and economic perspectives in relation.
Decision Modeling Techniques HINF Medical Methodologies Session 3.
Extending Medical Preference Models to Include Lifetime Goals Gordon Hazen Northwestern University INFORMS Pittsburgh, November 2006.
EQUILIBRIUM POPULATION METHODS FOR MARKOV MODELS OF HEALTH INTERVENTIONS Gordon Hazen, Ph.D., Min Huang. IEMS Department, Northwestern University Intervention.
1 Decision Trees and Influence Diagrams. 2 Constructing a decision tree: An initial tree...
Design of Health Technologies lecture 19 John Canny 11/14/05.
Extending the Qaly Model to Incorporate Goals that Are Not Time Modulated Gordon Hazen Northwestern University.
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk.
Assessing cost-effectiveness – what is an ICER?- Incremental analysis
Judgment and Decision Making in Information Systems Computing with Influence Diagrams and the PathFinder Project Yuval Shahar, M.D., Ph.D.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Decision Analysis. Real Case 63 year old housewife with 6 grown children. 10 year history of stable angina pectoris. 8 years ago she had total hip replacement.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
Evidence Based Medicine and Medical Decision Making Iztok Hozo, Professor of Mathematics Indiana University Northwest European School of Oncology How to.
Kevin Agostino NOSM Medical Student Dr. Saleem Malik Associate Professor NOSM.
Cost-effectiveness Analysis: Overview & Developing an analysis Training in Clinical Research DCEA Lecture 3 UCSF Department of Epidemiology and Biostatistics.
Acute Stroke: Principles of Modern Management A program of the American Academy of Neurology The AAN Acute Stroke Management courses are supported in part.
Outcomes in Decision Analysis: Utilities, QALYs & DALYs, and Discounting DCEA 24 January 2013 James G. Kahn.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
Cost-effectiveness Analysis: Overview; Developing an analysis Advanced Training in Clinical Research DCEA Lecture 3 UCSF Department of Epidemiology and.
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
Long-term mortality after acute stroke  Stroke is a leading cause of mortality: 6 million fatal events annually worldwide.  Mainly affects elderly, but.
Stroke. Stroke Facts About 795,000 Americans experience a Stroke (or Brain Attack) each year. About 610,000 of these are first attacks and 185,000 are.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Measures of Disease Frequency
Finding the Evidence Approximately 8,000 completed references are added to MEDLINE each week (over 400,000 added per year) Too much for any one person.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
● The results of this study suggest that using the prognostic test to guide ACT decisions in NSCLC is cost-effective compared to a SoC approach according.
STICH CABG Objective To determine whether surgery plus medical management or medical management alone improve outcomes in CABG patients Study Design 1212.
EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.
1 Cost efficacy of smoking cessation interventions Robert West University College London Logroño, October
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Practical Issues in Counseling Healthy Women About.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Date of download: 5/31/2016 From: Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med. 2008;148(12): doi: /
Methods Background Abstract Probability Parameters Selected References Genetic testing for BRCA mutations in high-risk women is cost-effective under base-
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
Date of download: 6/21/2016 From: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis.
Date of download: 6/26/2016 From: Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services.
How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.
(p for noninferiority = 0.01)
American Heart Month Resources:
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.
Recurrent Angina: New Tools for an Old Problem
Terms of Use. Terms of Use.
Mean eGFR among survivors after CABG surgery vs all-cause deaths
Decision Trees and Influence Diagrams.
DECISIONS CHANGING TIME AND MANNER OF DYING
A white elephant or the elephant in the room
Baseline Characteristics
Heart Attack vs. Cardiac Arrest
Cost-effectiveness of screening for asymptomatic carotid stenosis
Final CM for the early HTA of current and novel heart valve interventions. Final CM for the early HTA of current and novel heart valve interventions. Cerebrovascular.
Asymptomatic 67-year-old man prior to orthopaedic surgery with three cardiac risk factors and borderline ST-segment depression inferior-posterior on treadmill.
Schematic overview of diabetes-associated microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (cerebrovascular, coronary artery,
Health profile used in workshops to help people make diabetes management decisions. Health profile used in workshops to help people make diabetes management.
Pamela E. Scott et al. JACC 2018;71:
Cases of and deaths from prostate cancer, with associated age-standardized incidence and mortality (per men), among Canadian men aged 45 years.
Presentation transcript:

Factored stochastic tree modeling for medical decision making Gordon Hazen Northwestern University Rowland Chang Northwestern University James Pellissier Loyola University/Merck Pharmaceuticals

2 What is a stochastic tree? –Basic concepts……………………………….. –Stochastic tree transformation and rollback…. –Approximating human survival………………. –Factoring out mortality……………………….. Factoring stochastic trees…………………. Discounting / Risk aversion………………. Influence diagrams for stochastic models… Our THA model…………………………... The StoTree modeling environment………. Cost-effectiveness for THA……………….. Outline of talk

3 What is a stochastic tree? A stochastic tree is –A decision tree with stochastic nodes added –A continuous-time Markov chain with chance and decision nodes added –A multi-state DEALE model –A continuous-time version of a Markov cycle tree Stochastic Trees Continuous-time MCs Decision Trees Discrete-time MCs / Markov cycle trees DEALE

4 …What is a stochastic tree? Matchar & Pauker (1986): Transient ischemic attacks in a man with coronary artery disease

5 …What is a stochastic tree? Roach et al. (1988): Prostate cancer in a man with asymptomatic HIV

6 Markov cycle tree

7 Transforming stochastic trees = Superposition / Decomposition

8 …Transforming stochastic trees = Eliminating self-transitions

9 …Transforming stochastic trees

10 Stochastic tree rollback = v(x) = Quality rate at x L(x) = Mean quality-adjusted duration beginning at x Recursive formula:

11 Stochastic tree rollback

12 Approximating human survival

13 Coxian approximation to human mortality

14 Coxian approximation to human mortality

15 Factoring out mortality

16 …Factoring out mortality Background mortality Stroke morbidity

17 …Factoring out mortality Background mortality Stroke morbidity

18 Equivalent product tree

19 Rollback with Coxian mortality

20 Factored stochastic trees Cancer AIDS Background mortality

21 …Factoring stochastic trees Systemic embolism Pulmonary embolism Systemic hemorrhage Tsevat et al. (1986): Warfarin for dilated cardiomyopathy

22 Discounting / Risk aversion G = Utility function yielding quality-adjusted duration Utility function yielding discounted quality-adjusted duration Rollback with discounting

23 Modeling risk attitude ~ Vaccine scenario: What chance p of immediate death would you take to reduce your ongoing mortality rate by a percentage c? Undiscounted quality-adjusted duration forces: p = c Discounted quality-adjusted duration allows p < c (risk aversion)

24 Continuous-risk utility assessment

25 Influence diagrams Decision treeInfluence diagram

26 Influence diagrams with stochastic nodes

27 THA model

28 ACR functional status

29 THA vs. Conservative Management

30 ACR Functional Status / Initial THA Outcome

31 Prosthesis Status After THA

32 Last Surgery

33 Conservative Management

34 The StoTree modeling environment

35 …StoTree modeling environment

36...StoTree modeling environment

37 Rollback in the THA model 85-year-old white male

38 Cost-effectiveness for THA 85-year-old white male

39 THA Cost-Effectiveness Results